Skip to main content
. Author manuscript; available in PMC: 2025 Dec 24.
Published in final edited form as: Sleep Med. 2025 Oct 14;136:106853. doi: 10.1016/j.sleep.2025.106853

Fig. 3.

Fig. 3.

Percent change in AHI and SASHB by tertile analysis based on percent body weight change in participants treated with tirzepatide. Data are mean ± SD unless otherwise specified. Tertiles were based on percent body weight reduction, which was ≥22.33 % in the Upper, <22.33 % to ≥15.65 % in the Middle, and <15.65 % in the Lower for Study 1, and ≥23.42 % in the Upper, <23.42 % to ≥16.23 % in the Middle, and <16.23 % in the Lower for Study 2. AHI = apnea-hypopnea index; SASHB = sleep apnea-specific hypoxic burden; SD = standard deviation; TZP = tirzepatide maximum tolerated dose (MTD, 10 mg or 15 mg once weekly).